Mineralys Therapeutics Inc (MLYS) returns
Mineralys Therapeutics returns over 3 years
$1,000 invested in Mineralys Therapeutics three years ago was worth $2,253 at the close on October 30, 2026, with dividends reinvested: an average return of 31.1% a year. The same $1,000 in the S&P 500 (SPY) became $1,885.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -27.7% | — | $723.44 | -0.9% |
| 3 months | -30.6% | — | $694.16 | +2.1% |
| Year to date | -49.9% | — | $500.96 | +11.7% |
| 1 year | -55.8% | — | $442.12 | +12.4% |
| 3 years | +125.3% | +31.1% | $2,253 | +88.5% |
Mineralys Therapeutics return by calendar year
| Year | MLYS | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -49.9% | +11.7% | -61.6% |
| 2025 | +194.8% | +17.7% | +177.1% |
| 2024 | +43.1% | +24.9% | +18.3% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also:
No forecast, no recommendation. This page describes Mineralys Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.